Yuhki Yokoyama

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression

Hengrui Zhu, Fee Bengsch, Nikolaos Svoronos et al. · Cell Reports · 2016 · 417 citations · Full text

Cancer Immunosurveillance, Pd-l1 Expression, Pd-l1 Signaling +10

BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer

Sergey Karakashev, Hengrui Zhu, Yuhki Yokoyama et al. · Cell Reports · 2017 · 168 citations · Full text

Global loss of a nuclear lamina component, lamin A/C, and <scp>LINC</scp> complex components <scp>SUN</scp>1, <scp>SUN</scp>2, and nesprin‐2 in breast cancer

Ayaka Matsumoto, Miki Hieda, Yuhki Yokoyama et al. · Cancer Medicine · 2015 · 144 citations · Full text

Global Loss, Breast Oncology, Pathology +21

BET Inhibitors Suppress ALDH Activity by Targeting <i>ALDH1A1</i> Super-Enhancer in Ovarian Cancer

Yuhki Yokoyama, Hengrui Zhu, Jeong Heon Lee et al. · Cancer Research · 2016 · 142 citations · Full text

Oncology, Chemoprevention Strategy, Epigenetic Regulation +15

Cancer‐associated upregulation of histone H3 lysine 9 trimethylation promotes cell motility <i>in vitro</i> and drives tumor formation <i>in vivo</i>

Yuhki Yokoyama, Miki Hieda, Yu Nishioka et al. · Cancer Science · 2013 · 141 citations · Full text

Histone Modifications, Histone H3, Epigenetic Change +20